AN INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL EFFICACY AND

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 评估与帕米膦酸盐治疗患者相比，唑来膦酸治疗的重度骨质疏松症患者第12个月腰椎骨密度相对于基线的百分比变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To assess the percentage change in lumbar spine bone mineral density at month 12 relative to baseline in zoledronic acid treated patients with severe oseogenisis imperfecta compared to pamidronate treated patients.